GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2007

LigoCyte and Biogen Idec Ally to Develop Anti-CD103 Drugs

  • LigoCyte Pharmaceuticals inked a partnership with Biogen Idec to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases.

    CD103 is a alphaE-beta7 integrin that has been implicated in the activation, homing, and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs.

    LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for codevelopment, copromotion, and sharing of profits resulting from commercialized products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »